NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
Items 101–200 of 1,000
Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway
Su, X., Jiang, X., Meng, L., Dong, X., Shen, Y., & Xin, Y. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/5438179 · Cited by 170
Liu, Y., Guo, J.-Z., Liu, Y., Wang, K., Ding, W., Wang, H., Liu, X., Zhou, S., Lu, X.-C., Yang, H.-B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06841-7 · Cited by 165
Li, F., Han, X., Li, F., Wang, R., Wang, H., Gao, Y., Wang, X., Fang, Z., Zhang, W., Yao, S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.001 · Cited by 169
“We performed immunohistochemistry (IHC) to compare expression of NQO1, the prototypical target of antioxidant transcription factor NFE2-related factor 2 (NRF2) (Sporn and Liby, 2012).”
Gao, A.-M., Ke, Z.-P., Wang, J.-N., Yang, J.-Y., Chen, S.-Y., & Chen, H. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt108 · Cited by 168
Regulation of the Keap1–Nrf2 pathway by p62/SQSTM1
Katsuragi, Y., Ichimura, Y., & Komatsu, M. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.005 · Cited by 168
Mechanism of Apoptosis Induced by Curcumin in Colorectal Cancer
Ismail, N. I., Othman, I., Abas, F., H. Lajis, N., & Naidu, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102454 · Cited by 166
Augsten, M., Sjöberg, E., Frings, O., Vorrink, S. U., Frijhoff, J., Olsson, E., Borg, Å., & Östman, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2740 · Cited by 164
Nrf2-Mediated Fibroblast Reprogramming Drives Cellular Senescence by Targeting the Matrisome
Hiebert, P., Wietecha, M. S., Cangkrama, M., Haertel, E., Mavrogonatou, E., Stumpe, M., Steenbock, H., Grossi, S., Beer, H.-D., Angel, P., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.06.012 · Cited by 165
Reactive oxygen species and DNA damage response in cancer
Renaudin, X. (2021) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2021.04.001 · Cited by 162
Potential Applications of NRF2 Modulators in Cancer Therapy
Panieri, E., Buha, A., Telkoparan-Akillilar, P., Cevik, D., Kouretas, D., Veskoukis, A., Skaperda, Z., Tsatsakis, A., Wallace, D., Suzen, S., et al. (2020) · Antioxidants · doi:10.3390/antiox9030193 · Cited by 161
“Moreover, many findings indicate that ROS levels should be suppressed in order to prevent cancer development due to their involvement in promoting and sustaining carcinogenesis [62,159].”
BackgroundSQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer
Li, L., Shen, C., Nakamura, E., Ando, K., Signoretti, S., Beroukhim, R., Cowley, G. S., Lizotte, P., Liberzon, E., Bair, S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.025 · Cited by 161
“…and functional evidence that NRF2, which activates a transcriptional program that promotes resistance to redox stress, can promote tumor growth in some 746 Cancer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc. settings (DeNicola et al., 2011; Hayes and McMahon, 2009; Sporn and Liby, 2012).”
Esteras, N., Dinkova-Kostova, A. T., & Abramov, A. Y. (2016) · Biological Chemistry · doi:10.1515/hsz-2015-0295 · Cited by 160
“For those reasons, taking into account the context is essential in designing Nrf2 therapeutic approaches (Sporn and Liby, 2012).”
BackgroundBai, X., Chen, Y., Hou, X., Huang, M., & Jin, J. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1197239 · Cited by 157
“Epigenetic and post-translational modifications of KEAP1 (Ooi et al., 2011; Sporn & Liby, 2012) and increasing disruptor proteins such as p62 (Ryoo et al., 2015) also disrupt their interact and the inhibitory effect of KEAP1 on NRF2.”
BackgroundNRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
Weiss‐Sadan, T., Ge, M., Hayashi, M., Gohar, M., Yao, C.-H., de Groot, A., Harry, S. A., Carlin, A. D., Fischer, H., Shi, L., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.012 · Cited by 172
The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase
Sanghvi, V. R., Leibold, J., Mina, M., Mohan, P., Berishaj, M., Li, Z., Miele, M. M., Lailler, N., Zhao, C., de Stanchina, E., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.031 · Cited by 155
Arsenic and Human Health: Genotoxicity, Epigenomic Effects, and Cancer Signaling
Öztürk, M., Metin, M., Altay, V., Bhat, R. A., Ejaz, M., Gul, A., Ünal, B. T., Hasanuzzaman, M., Nibir, L., Nahar, K., et al. (2021) · Biological Trace Element Research · doi:10.1007/s12011-021-02719-w · Cited by 160
Pastorelli, D., Fabricio, A. S. C., Giovanis, P., D'Ippolito, S., Fiduccia, P., Soldà, C., Buda, A., Sperti, C., Bardini, R., Dalt, G. D., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.013 · Cited by 167
“Genetic studies on some cancers, indeed, point out constitutive Nrf2 activation as a possible cause of an increased resistance to chemotherapy [35,36].”
Magrone, T., Magrone, M., Russo, M. A., & Jirillo, E. (2019) · Antioxidants · doi:10.3390/antiox9010035 · Cited by 179
“Finally, curcumin and epigallocatechin gallate (EGCG) are able to activate antioxidant enzymes, such as superoxide dismutase, catalase, and glutathione peroxidase, thus leading to ROS detoxification [45,46].”
BackgroundKang, K. A., Piao, M. J., Kim, K. C., Kang, H. K., Chang, W. Y., Park, I. C., Keum, Y. S., Surh, Y. J., & Hyun, J. W. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.149 · Cited by 149
“Recent studies showed that Nrf2 expression is upregulated in various human cancers, suggesting its possible involvement in carcinogenesis during several stages of cancer, such as initiation, progression, and resistance to chemotherapy.(16,17) Recently, it has been reviewed that Nrf2 and its principal target protein HO…”
BackgroundHou, N., Liu, N., Han, J., Yan, Y., & Li, J. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000430 · Cited by 148
Gai, C., Yu, M., Li, Z., Wang, Y., Ding, D., Zheng, J., Lv, S., Zhang, W., & Li, W. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29221 · Cited by 152
“Nrf2 inhibition reversed erastin or artesunate‐induced ferroptosis through regulating redox homeostasis (Gorrini, Harris, & Mak, 2013; Roh, Kim, Jang, & Shin, 2017; Sporn & Liby, 2012).”
Bal-Price, A., Pistollato, F., Sachana, M., Bopp, S. K., Munn, S., & Worth, A. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.02.008 · Cited by 148
“More recently, we reported that rotenone-dependent activation of the Nrf2 signaling pathway, a master regulator of antioxidant response (Sporn and Liby, 2012), elicited astroglial cell reactivity and dopaminergic neuronal cell death in IMR90-hiPSC-derived NPCs further differentiated into neurons and glia (Pistollato e…”
BackgroundNon-thermal Plasma Activates Human Keratinocytes by Stimulation of Antioxidant and Phase II Pathways
Schmidt, A., Dietrich, S., Steuer, A., Weltmann, K., von Woedtke, T., Masur, K., & Wende, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.603555 · Cited by 149
“Several studies have suggested that the beneficial effects of chemopreventive drugs on the suppression of carcinogenesis are mediated through activation of NRF2 (86).”
BackgroundA catalogue of somatic NRF2 gain-of-function mutations in cancer
Kerins, M. J., & Ooi, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31281-0 · Cited by 140
Redox Environment, Free Radical, and Oxidative DNA Damage
Storr, S. J., Woolston, C. M., Zhang, Y., & Martin, S. G. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4920 · Cited by 151
“NRF2 can bind antioxidant response elements (AREs) or electrophile response elements (EpREs) on DNA and can induce the expression of important enzymes such as catalase (reviewed in (89)).”
Controversy about pharmacological modulation of Nrf2 for cancer therapy
Milkovic, L., Zarkovic, N., & Saso, L. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.013 · Cited by 142
“Furthermore, Nrf2 was recognized as “a key regulator in chemotherapeutic resistance under hypoxia through ROS-Nrf2-GCLCGSH pathway” in breast cancer cells [39].”
BackgroundXu, B., Wang, S., Li, R., Chen, K., He, L., Deng, M., Kannappan, V., Zha, J., Dong, H., & Wang, W. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.176 · Cited by 140
Localization, tissue biology and T cell state — implications for cancer immunotherapy
Schenkel, J. M., & Pauken, K. E. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00884-8 · Cited by 152
“…can be highly dependent on the types of mutations each tumour has (for example, KEAP1 mutation in lung cancer drives a distinct metabolic state) 197 and on the tissue the tumours are located in, even when the tumours are of the same origin (for example, pancreatic tumours in the pancreas and…”
BackgroundZheng, Z., Xu, H., Suo, S., Xu, X., Ni, M., Gu, L., Chen, W., Wang, L., Zhao, Y., Tian, B., et al. (2016) · Scientific Reports · doi:10.1038/srep26093 · Cited by 151
The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context
Xing, F., Hu, Q., Qin, Y., Xu, J., Zhang, B., Yu, X., & Wang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.862743 · Cited by 154
“Sustained accumulation or activation of Nrf2 and subsequent upregulation of antioxidants results in an environment conducive to the survival and growth of malignant cells (46).”
BackgroundCOPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link
Bozinovski, S., Vlahos, R., Anthony, D., McQualter, J. L., Anderson, G. P., Irving, L. B., & Steinfort, D. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13198 · Cited by 149
“Agents that increase NFE2L2 expression have shown promise in pre-clinical models of lung cancer when administered during the initiation phase of carcinogenesis, and consequently, there has been interest in their use as cancer chemopreventative agents (reviewed in Sporn and Liby, 2012).”
BackgroundThe PTEN/NRF2 Axis Promotes Human Carcinogenesis
Rojo, A. I., Rada, P., Mendiola, M., Ortega-Molina, A., Wojdyla, K., Rogowska-Wrzesinska, A., Hardisson, D., Serrano, M., & Cuadrado, A. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5843 · Cited by 135
“An increasing number of reports indicate that NRF2 provides a protective advantage to tumor cells against the oxidative stress which is produced under high proliferation rates (51).”
Wang, J., Shanmugam, A., Markand, S., Zorrilla, E., Ganapathy, V., & Smith, S. B. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.009 · Cited by 133
“Nrf2 is arguably the most important regulator of the expression of antioxidant molecules [33], thus this first report that lack of σ1R is linked to decreased Nrf2 levels could provide important clues to the mechanism by which σ1R acts as a mediator of oxidative stress as well as to the mechanism”
BackgroundCogoi, S., Ferino, A., Miglietta, G., Pedersen, E. B., & Xodo, L. E. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1142 · Cited by 135
“Indeed, in agreement with previous work (63), we found that the inhibition of Nrf2 brought about an increase of ROS in Panc-1 cells (Supplementary Figure S9).”
Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia
Syu, J.-P., Chi, J.-T., & Kung, H.-N. (2016) · Oncotarget · doi:10.18632/oncotarget.7406 · Cited by 132
Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy
Basak, P., Sadhukhan, P., Sarkar, P., & Sil, P. C. (2017) · Toxicology Reports · doi:10.1016/j.toxrep.2017.06.002 · Cited by 147
Mitochondrial Calcium Regulation of Redox Signaling in Cancer
Delierneux, C., Kouba, S., Shanmughapriya, S., Potier‐Cartereau, M., Trebak, M., & Hempel, N. (2020) · Cells · doi:10.3390/cells9020432 · Cited by 146
“A well-studied example of this in cancer cells is the transcriptional regulation of antioxidant enzymes by Nrf2 (nuclear factor erythroid-derived 2-like 2; NFE2L2) [90].”
BackgroundThe mutational landscape of hepatocellular carcinoma
Lee, J. (2015) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2015.21.3.220 · Cited by 146
Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance
Saddawi-Konefka, R., Seelige, R., Gross, E. T. E., Levy, E., Searles, S. C., Washington, A., Santosa, E. K., Liu, B., O’Sullivan, T. E., Harismendy, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.075 · Cited by 126
“In contrast to the tumor suppressor role of Nrf2, other studies have shown that Nrf2 expression in tumor cells can promote their survival in the face of oxidative stress, hypoxia, and/or chemotherapy (Jaramillo and Zhang, 2013; Sporn and Liby, 2012).”
Zheng, C., Zhang, B., Li, Y., Liu, K., Wei, W., Liang, S., Guo, H., Ma, K., Liu, Y., Wang, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202206798 · Cited by 158
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
Rocha, C. R. R., Kajitani, G. S., Quinet, A., Fortunato, R. S., & Menck, C. F. M. (2016) · Oncotarget · doi:10.18632/oncotarget.10129 · Cited by 135
“In this work, we showed that upon TMZ treatment there was an increase on ROS production due, at least in part, to mitochondria damage, which seems to be the trigger for the induction of NRF2 and consequently increase GCLM and GSTπ expression upon TMZ treatment.”
BackgroundInfluentialActivation of p62/SQSTM1–Keap1–Nuclear Factor Erythroid 2-Related Factor 2 Pathway in Cancer
Ichimura, Y., & Komatsu, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00210 · Cited by 140
KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease
Naidu, S. D., & Dinkova‐Kostova, A. T. (2020) · Open Biology · doi:10.1098/rsob.200105 · Cited by 145
Hatem, E., El Banna, N., & Huang, M.-E. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7134 · Cited by 127
“The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is a master transcriptional regulator of cellular antioxidant systems (135).”
Sharma, S., Shree, B., Sharma, D., Kumar, S., Kumar, V., Sharma, R. C., & Saini, R. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111038 · Cited by 149
Role of Phytochemicals in Skin Photoprotection via Regulation of Nrf2
Chaiprasongsuk, A., & Panich, U. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.823881 · Cited by 145
“…under stress and inflammatory conditions, several studies have discussed a detrimental aspect of Nrf2 defined as the “dark side of Nrf2” in the cancer biology as enhanced Nrf2 activity is involved in a pro-carcinogenic effect and therapeutic resistance of cancer cells (Sporn and Liby, 2012).”
BackgroundJiang, Z.-Y., Lu, M.-C., & You, Q.-D. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00586 · Cited by 121
Oxidative Stress in Cells with Extra Centrosomes Drives Non-Cell-Autonomous Invasion
Arnandis, T., Monteiro, P., Adams, S. D., Bridgeman, V. L., Rajeeve, V., Gadaleta, E., Marzec, J., Chelala, C., Malanchi, I., Cutillas, P. R., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.10.026 · Cited by 129
“stabilized in response to oncogenes such as K-RAS and MYC and is essential for tumor detoxification and growth (DeNicola et al., 2011; Sporn and Liby, 2012).”
BackgroundIntegrative clinical and molecular characterization of translocation renal cell carcinoma
Bakouny, Z., Sadagopan, A., Ravi, P. K., Metaferia, N. Y., Li, J., AbuHammad, S., Tang, S., Denize, T., Garner, E. R., Gao, X. Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110190 · Cited by 126
Nrf2 in health and disease: current and future clinical implications
Al-Sawaf, O., Clarner, T., Fragoulis, A., Kan, Y. W., Pufe, T., Streetz, K., & Wruck, C. J. (2015) · Clinical Science · doi:10.1042/cs20150436 · Cited by 125
Phytoagents for Cancer Management: Regulation of Nucleic Acid Oxidation, ROS, and Related Mechanisms
Lee, W.-L., Huang, J.-Y., & Shyur, L. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/925804 · Cited by 141
“However, recent studies indicate that Nrf2 itself also plays a double-bladed-sword role in cancer management [185].”
Lin, D., Dinh, H. Q., Xie, J., Mayakonda, A., Silva, T. C., Jiang, Y., Ding, L., He, J., Xu, X., Hao, J., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-314607 · Cited by 130
Kalyanaraman, B. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102497 · Cited by 138
Sun, S., Liu, Z., Lin, M., Gao, N., & Wang, X. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1456730 · Cited by 150
Sánchez-Ortega, M., Carrera, A. C., & Garrido, A. (2021) · Cells · doi:10.3390/cells10081879 · Cited by 140
“However, at advanced stages, some actions of NRF2 can promote carcinogenesis [25].”
BackgroundInfluentialIdentification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis
Hendricks, J. M., Doubravsky, C. E., Wehri, E., Li, Z., Roberts, M. A., Deol, K. K., Lange, M., Lasheras-Otero, I., Momper, J. D., Dixon, S. J., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.04.007 · Cited by 136
Zhao, J., Zhai, L., Liu, Z., Wu, S., & Xu, L. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/190945 · Cited by 133
Petrelli, A., Perra, A., Cora, D., Sulas, P., Menegon, S., Manca, C., Migliore, C., Kowalik, M. A., Ledda-Columbano, G. M., Giordano, S., et al. (2014) · Hepatology · doi:10.1002/hep.26616 · Cited by 121
“3C), whose role in cancer development has recently become a topic of an important controversy.(17) The finding that the majority of NRF2 target genes were up-regulated indicates activation of the NRF2 pathway (Fig.”
BackgroundProtective Role of Nrf2 in Renal Disease
Guerrero‐Hue, M., Rayego‐Mateos, S., Vázquez‐Carballo, C., Palomino‐Antolín, A., García‐Caballero, C., Opazo-Ríos, L., Morgado‐Pascual, J. L., Herencia, C., Mas, S., Ortíz, A., et al. (2020) · Antioxidants · doi:10.3390/antiox10010039 · Cited by 139
“Moreover, this domain interacts with the E2 ubiquitin-binding enzyme UbcM2 (an E2-type ubiquitin-binding enzyme) to regulate the stability of Nrf2 [17] and allows DNA binding and modulation of numerous genes through its association with ARE (antioxidant response element) sequences in specific gene promoter regions [18…”
BackgroundCigarette Smoke-Induced Respiratory Response: Insights into Cellular Processes and Biomarkers
Cha, S.-R., Jang, J., Park, S., Ryu, S. M., Cho, S.-J., & Yang, S. (2023) · Antioxidants · doi:10.3390/antiox12061210 · Cited by 163
Staurengo‐Ferrari, L., Badaro‐Garcia, S., Hohmann, M. S., Manchope, M. F., Zaninelli, T. H., Casagrande, R., & Verri, W. A., Jr. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01536 · Cited by 133
Zhang, Q., Li, Y.-W., Liu, Z., & Chen, Q.-L. (2016) · Aquatic Toxicology · doi:10.1016/j.aquatox.2016.10.029 · Cited by 122
Metabolic features of cancer cells
Wang, Y., Xia, Y., & Lu, Z. (2018) · 癌症:英文版 · doi:10.1186/s40880-018-0335-7 · Cited by 125
“Nuclear factor erythroid 2-related factor 2 (Nrf2), a master transcriptional regulator of enzymes, is activated in response to oxidative and electrophilic stress and plays an essential role in cellular redox homeostasis [42].”
BackgroundPhytochemicals: Current strategy to sensitize cancer cells to cisplatin
Sun, C., Zhang, Q.-Y., Zheng, G., & Feng, B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.010 · Cited by 130
Yang, B., Zhou, Y., Wu, M., Li, X., Mai, K., & Ai, Q. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02750-0 · Cited by 123
Tang, Y.-C., Hsiao, J., Jiang, S.-S., Chang, J., Chu, P., Liu, K., Fang, H.-L., Lin, L.-M., Chen, H.-H., Huang, Y., et al. (2021) · Theranostics · doi:10.7150/thno.53417 · Cited by 128
“However, recent evidence has revealed that aberrant activation of NRF2 is associated with cancer hallmarks [4-10], including promoted tumorigenesis [11, 12], sustained”
BackgroundBaldelli, S., Aquilano, K., & Ciriolo, M. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.006 · Cited by 127
DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer
Zhang, Q., Zhang, Z.-Y., Du, H., Li, S., Tu, R., Jia, Y., Zheng, Z., Song, X., Du, R., & Zhang, X. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0303-z · Cited by 119
Shahcheraghi, S. H., Salemi, F., Small, S., Syed, S., Salari, F., Alam, W., Cheang, W. S., Saso, L., & Khan, H. Z. (2023) · Phytotherapy Research · doi:10.1002/ptr.7754 · Cited by 128
“Histological and ultrastructural observations also provided evidence that RES effectively protected the kidneys from hyperglycemia-mediated oxidative damage (Palsamy & Subramanian, 2011; Sporn & Liby, 2012; Szkudelski & Szkudelska, 2015).”
Backgroundp62/SQSTM1 synergizes with autophagy for tumor growth in vivo
Wei, H., Wang, C., Croce, C. M., & Guan, J. (2014) · Genes & Development · doi:10.1101/gad.237354.113 · Cited by 126
Choi, E.-J., Jung, B.-J., Lee, S.-H., Yoo, H.-S., Shin, E.-A., Ko, H., Chang, S., Kim, S.-Y., & Jeon, S.-M. (2017) · Oncogene · doi:10.1038/onc.2017.153 · Cited by 119
Zhu, J., Xiong, Y., Zhang, Y., Wen, J., Cai, N., Cheng, K., Liang, H., & Zhang, W. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8810785 · Cited by 125
“NRF2 is generally considered the most significant modulator of intracellular antioxidant response [73].”
BackgroundTsakiri, E. N., Sykiotis, G. P., Papassideri, I. S., Terpos, E., Dimopoulos, M. A., Gorgoulis, V. G., Bohmann, D., & Trougakos, I. P. (2013) · Aging Cell · doi:10.1111/acel.12111 · Cited by 113
“Together with the findings of constitutive Nrf2 and/or proteasome activation in various human cancers (Ruschak et al., 2011; Sporn & Liby, 2012; Trougakos et al., 2013), these observations pose warnings against prolonged uncontrolled pharmacological stimulation of Nrf2 and/or proteasome in…”
BackgroundToyokuni, S. (2016) · Pathology International · doi:10.1111/pin.12396 · Cited by 111
p62/SQSTM 1—Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer
Taniguchi, K., Yamachika, S., He, F., & Karin, M. (2016) · FEBS Letters · doi:10.1002/1873-3468.12301 · Cited by 112
“However, it is somewhat controversial whether NRF2 functions as an oncogene or a tumor suppressor [86, 100-103].”
BackgroundWDR23 regulates NRF2 independently of KEAP1
Lo, J. Y., Spatola, B. N., & Curran, S. P. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006762 · Cited by 111
“Cellular adaptation to stress (oxidative, xenobiotic, dietary) is essential to ensure organismal survival, and NRF2 is an exceptionally well-studied and key determinant of cellular stress responses[2, 11].”
Vučetić, M., Cormerais, Y., Parks, S. K., & Pouysségur, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00319 · Cited by 111
“The best example is the nuclear factor (erythroid-derived-2)-like 2 (NRF2)-signaling pathway [reviewed elsewhere in great detail (34, 35)].”
BackgroundNrf2/ARE Pathway Modulation by Dietary Energy Regulation in Neurological Disorders
Vasconcelos, A. R., dos Santos, N. B., Scavone, C., & Munhoz, C. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00033 · Cited by 123
“However, controversial reports showed that NRF2 activation can result in drug resistance and oncogenic effects (Sporn and Liby, 2012).”
BackgroundNRF2 and p53: Januses in cancer?
Rotblat, B., Melino, G., & Knight, R. A. (2012) · Oncotarget · doi:10.18632/oncotarget.754 · Cited by 109
“While these mechanisms are important to prevent disease onset, it is now becoming evident that the same mechanisms are being exploited by cancer cells in order to survive and thrive under oxidative stress insults and to armor themselves against therapeutic interventions that rely on oxidative stress as their mechanism…”
BackgroundTargeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer
Sourbier, C., Ricketts, C. J., Matsumoto, S., Crooks, D. R., Liao, P., Mannes, P. Z., Yang, Y., Wei, M.-H., Srivastava, G. K., Ghosh, S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.005 · Cited by 115
“Because NRF2 plays a critical role in cellular defense against ROS (Sporn and Liby, 2012), we tested whether the vandetanib sensitivity of these cells might be affected by cellular ROS level.”
BackgroundDichotomous roles of TGF-β in human cancer
Huang, J. J., & Blobe, G. C. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160065 · Cited by 121
Zha, J., Chen, F., Dong, H., Shi, P., Yao, Y., Zhang, Y., Li, R., Wang, S., Li, P., Wang, W., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-163 · Cited by 108
“Nrf2 is a transcription factor which plays a vital role in activating antioxidant response that decreases ROS [3].”
BackgroundInfluentialTargeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities
Bernardo, I., Bozinovski, S., & Vlahos, R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.08.005 · Cited by 116
“Severalstudies have foundthatNrf2-activatingcompoundscan prevent or suppress cancer in mouse models (Sporn & Liby, 2012).”
BackgroundChen, N., Wu, L., Yuan, H., & Wang, J. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10564 · Cited by 113
“By transcriptional regulation of a variety of detoxification enzymes such as heme oxyegenase-1 (HO-1), NAD(P)H: quinone oxidoreductase 1 (NQO1), Nrf2 protects cells against oxidative stress caused damages [16-20].”
BackgroundKim, S., Indu Viswanath, A. N., Park, J.-H., Lee, H. E., Park, A. Y., Choi, J. W., Kim, H. J., Londhe, A. M., Jang, B. K., Lee, J., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107989 · Cited by 105
Redox Imbalance in the Development of Colorectal Cancer
Liu, H., Liu, X., Zhang, C., Zhu, H., Xu, Q., Bu, Y., & Lei, Y. (2017) · Journal of Cancer · doi:10.7150/jca.18735 · Cited by 115
“In addition to serving as a ROS-sensitive transcription factor, Nrf2 is the most important intracellular regulator of antioxidants [114].”
BackgroundSatoh, T., & Lipton, S. A. (2017) · F1000Research · doi:10.12688/f1000research.12111.1 · Cited by 106
The Hallmarks of Cancer from a Redox Perspective
Hornsveld, M., & Dansen, T. B. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6580 · Cited by 115
“In parallel with p21 cip1/waf1 function to halt the cell cycle, p21 cip1/waf1 also mediates the activation of NRF2, a major antioxidant response transcription factor (215).”
RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity
Probst, B., Isaac, T., Lyndsey, M., Bumeister, R., Dulubova, I., Wigley, W. C., & Ferguson, D. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122942 · Cited by 110
“Despite activation of Nrf2 by AIMs, preclinical studies have consistently demonstrated the anticancer activity of these compounds [51].”
BackgroundHanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy
Sharifi‐Rad, J., Seidel, V., Izabela, M., Monserrat-Mesquida, M., Sureda, A., Ormazábal, V., Zuñiga, F. A., Shetty, M. S., Pezzani, R., Ydyrys, A., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01109-0 · Cited by 121
“Therefore it is logical that both activators and inhibitors of Nrf2 could act in anticancer therapy [24].”
BackgroundLi, W., Guo, Y., Zhang, C., Wu, R., Yang, Y., Gaspar, J. M., & Kong, A. T. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00413 · Cited by 107
Metabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 113
NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest
Sun, X., Wang, Y., Ji, K., Liu, Y., Kong, Y., Nie, S., Li, N., Hao, J., Xie, Y., Xu, C., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa631 · Cited by 101
NRF2, a Key Regulator of Antioxidants with Two Faces towards Cancer
Kim, J., & Keum, Y. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2746457 · Cited by 111
“In the analysis of clinical samples, it was found that gain-of-functionmutations in NRF2 exist in carcinomas of esophagus, skin, and larynx, while loss-of-function mutations in KEAP1 are observed in carcinomas of lung, gall bladder, ovary, breast, liver, and stomach [51].”
BackgroundResultOridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway
Lü, Y., Sun, Y., Zhu, J., Yu, L., Jiang, X., Zhang, J., Dong, X., Ma, B., & Zhang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0031-6 · Cited by 101
Iranshahy, M., Iranshahi, M., Abtahi, S. R., & Karimi, G. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.07.024 · Cited by 107
Xu, D., Li, X., Shao, F., Lv, G., Lv, H., Lee, J.-H., Qian, X., Zheng, W., Xia, Y., Du, L., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4570 · Cited by 108
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Cancers · doi:10.3390/cancers13215557 · Cited by 110
“Aerobic glycolysis can decrease the production of ROSs [32] which, at low concentrations, can improve cancer cell survival rates [33] as long as glucose intake is maintained at the required level [34].”
BackgroundTranscriptional regulation of the stress response by mTOR
Aramburu, J., Ortells, M. C., Tejedor, S., Buxadé, M., & López-Rodríguez, C. (2014) · Science Signaling · doi:10.1126/scisignal.2005326 · Cited by 99
“The abundance of Nrf2 is controlled by a repressor, Kelch-like ECH-associated protein 1 (Keap1), which facilitates the ubiquitylation and subsequent proteasomemediated degradation of Nrf2 (86–88).”
BackgroundInfluential
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.